Axsome Therapeutics (AXSM) 10-K2024 FY Annual report

Filed: 18 Feb 25, 5:10pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: aminoketone, antipsychotic, biggest, BioXcel, Bolar, brain, Bright, cast, catastrophic, Centessa, Chevron, CODM, composed, conditionally, consecutive, consignment, Corner, cortical, covenant, CTA, CTD, CTR, deadline, dedicated, deep, dismissed, DNRI, Dogwood, donut, draft, EC, EEA, Eisai, ENCORE, era, exemption, explanation, extrapyramidal, FDORA, fleet, flourish, geography, gradually, hazard, Hezbollah, hole, HTA, inconsistent, institutionalization, introduced, Iran, irreversible, ix, Johnson, Kallyope, Lebanon, Loper, loved, Lumryz, Misclassification, mission, Montgomery, musculoskeletal, Neumora, Neurocrine, neuroscience, noncancelable, opposite, OSA, overhaul, overturned, PARADIGM, Parliament, passage, prejudice, preparatory, presidential, Raimondo, rationale, RDP, resell, reward, rulemaking, Sandoz, sberg, Squibb, streamline, structure, Subtopic, Symbravo, transformative, unallocated, verbal, vii, viral, workday, worsening, WPAI, Xenon, Yemen

Removed: abnormal, advancing, aggressive, allodynia, anemia, Anjeso, anticipation, Aptinyx, arrythmia, Belize, bilateral, blind, bother, bothersome, carved, chest, cigarette, Cohen, Colombia, comparator, Congressional, continually, Costa, decided, destroy, doctor, dosed, durably, dyspepsia, Ecuador, El, enabled, exhibited, fastest, favorably, flatulence, focal, fold, Foundation, freedom, gastric, gastroesophageal, gastrointestinal, Guatemala, hematuria, home, hour, indirect, infringer, INTERCEPT, jaw, kickback, mainstay, Malaysia, Mansfield, mechanistic, Med, mild, Minerva, missed, Mobic, moderate, MOMENTUM, morning, Multimechanistic, neck, Nicaragua, numerical, nursing, obesity, onset, Optimization, packaged, PBM, percent, Peru, PGIC, phonophobia, photophobia, placement, plasma, profit, progression, pulsating, recurrence, recurrent, reflux, reformulated, relieved, Relmada, respiratory, Rica, Sage, Salvador, separation, St, stabilization, strongly, sweating, syncope, threatening, throat, timepoint, trailing, treating, tremor, triptan, unilateral, upper, vision, Vivlodex

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated AXSM transcripts

AXSM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

STATEMENT OF PRINCIPAL EXECUTIVE OFFICER OF
AXSOME THERAPEUTICS, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Axsome Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Herriot Tabuteau, M.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: February 18, 2025	/s/ Herriot Tabuteau, M.D.
	Herriot Tabuteau, M.D. Chief Executive Officer (Principal Executive Officer)